Comparing two medicines (Itraconazole and Isotretinion) in treating seborrheic dermatitis
Comparison of the effect of low-dose oral Isotretinoin and Itraconazole on symptoms in seborrheic dermatitis
PNS SHIFA HOSPITAL
68 participants
Jul 1, 2025
Interventional
Conditions
Summary
Study design: Randomised control trial Intervention Description: A comparative study of low-dose oral Isotretinoin 20 mg/day twice weekly for three consecutive months and Itraconazole 200 mg/day during the 1st week of the 1st month, then 200 mg daily on 1st two days of every month for next two months in moderate to severe seborrheic dermatitis conducting at dermatology out-patient department PNS Shifa hospital ,Karachi. After written consent 68 patients are divided into Group A and B. Patients in both the groups will receive treatment for 3 months and data from the patients will be collected through a proforma on first visit and follow ups. Evaluation will be done through SDASI score at baseline, 4 weeks, 8 weeks and 12 weeks after commencement of treatment Outcomes will be assessed as: o Complete Resolution (90% Decrease or more of SDASI Score from Baseline) o Partial Improvement (25-90% Decrease in SDASI Score from Baseline) o No Improvement (< 25% Decrease in SDASI Score from Baseline) HYPOTHESIS: Proposition of this study is based on the belief that low dose oral isotretinoin has similar efficacy and safety to itraconazole for treatment of seborrheic dermatitis
Eligibility
Inclusion Criteria5
- Both Genders
- Adults aged 18–70 years.
- Clinical assessment using the SDASI (Seborrheic Dermatitis Area Severity Index),of moderate to severe Seborrheic dermatitis (a score of 4 and above).
- Agreeing to follow the instructions given in the course of the study and show up for follow-up examinations.
- Patients not taking any topical medication for Seborrheic Dermatitis for the last two months
Exclusion Criteria6
- Pregnant or breastfeeding women.
- Current use of systemic antifungals, or isotretinoin within the past half a year.
- Patients with any history of Hyperlipidemia, severe hepatic, renal or cardiac disease.
- Patients known to be hypersensitive to isotretinoin and itraconazole.
- Patients with uncontrolled Diabetes Mellitus, Malnourished, children or those receiving systemic immunosuppressants.
- Patients having mild Seborrheic Dermatitis
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Group A: Low-Dose Oral Isotretinoin (20 mg/day twice weekly for three consecutive months)
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12626000021370